Program
BMS-986310
Also written as “ONO-4578”.
Its studies are mostly in Stomach Neoplasms · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ono Pharmaceutical | 54 open or running | phase 3since Sep 9, 2026 | Mar 17, 2017 | Feb 15, 2028phase 2 · NCT06948448 |
| Bristol-Myers Squibb | 10 open or running | phase 1since Aug 30, 2018 | Aug 30, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 17, 2017First study: phase 1 study in Advanced or Metastatic Solid TumorsNew to Ono PharmaceuticalOno Pharmaceutical · NCT03155061 · 183 enrolled · Japan
- Aug 30, 2018Bristol-Myers Squibb's first study: phase 1 study in Advanced CancerNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT03661632 · 27 enrolled · United States, Belgium, Canada
- Jan 23, 2024Phase 2 study in Stomach NeoplasmsOno Pharmaceutical · NCT06256328 · 226 enrolled · Japan, South Korea, Taiwan
- Aug 1, 2024Phase 1 study in Carcinoma, Non-Small-Cell LungOno Pharmaceutical · NCT06542731 · 42 enrolled · Japan
- Apr 21, 2025Phase 2 study in Colorectal NeoplasmsOno Pharmaceutical · NCT06948448 · 144 planned · United States, Canada, France and more
- Sep 9, 2026Phase 3 study in Stomach NeoplasmsPhase 3 reachedOno Pharmaceutical · NCT07818070 · 600 planned
Ahead
- Feb 15, 2028Primary completion: phase 2 study in Colorectal NeoplasmsOno Pharmaceutical · NCT06948448
- Mar 2028Primary completion: phase 1 study in Advanced or Metastatic Solid TumorsOno Pharmaceutical · NCT03155061
- Jan 2031Primary completion: phase 3 study in Stomach NeoplasmsOno Pharmaceutical · NCT07818070
TargetBeta
“An orally bioavailable antagonist of the prostaglandin E2 receptor subtype 4 (PTGER4; EP4), ”NCIt, by rule
Other programs on PTGER4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| EP4 Receptor Antagonist YY001rule | chongqing-claruvis-pharmaceutical-co-ltd | phase 3 | 6 |
| EP2/EP4/DP1 Antagonist OKN4395rule | epkin | phase 1 | 1 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07818070Stomach Neoplasms | 3 | Not yet recruiting | Ono Pharmaceutical | Jan 2031 | 600 |
| NCT06948448Colorectal Neoplasms · United States, Canada, France and more | 2 | Recruiting | Ono Pharmaceutical | Feb 15, 2028 | 144 |
| NCT06542731Carcinoma, Non-Small-Cell Lung · Japan | 1 | Completed | Ono Pharmaceutical | Oct 30, 2025 | 42 |
| NCT06256328Stomach Neoplasms · Japan, South Korea, Taiwan | 2 | Active, not recruiting | Ono Pharmaceutical | Oct 9, 2025 | 226 |
| NCT03661632Advanced Cancer · United States, Belgium, Canada | 1 | Completed | Bristol-Myers Squibb | Nov 11, 2019 | 27 |
| NCT03155061Advanced or Metastatic Solid Tumors · Japan | 1 | Active, not recruiting | Ono Pharmaceutical | Mar 2028 | 183 |
How it is read
Names in the registry
- “ONO-4578”, 5 entries
- “BMS-986310”, 1 entry
Conditions, from the studies’ own filings
- Stomach Neoplasms, 2 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
- Colorectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.